Should I buy or sell ADC Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADCT, but not buy additional shares or sell existing shares. View ADCT analyst ratings or view top-rated stocks .

What is ADC Therapeutics' stock price target for 2024?

6 analysts have issued 12 month price targets for ADC Therapeutics' stock. Their ADCT share price targets range from $2.00 to $6.00. On average, they predict the company's stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 256.0% from the stock's current price. View analysts price targets for ADCT or view top-rated stocks among Wall Street analysts .

How have ADCT shares performed in 2023?

ADC Therapeutics' stock was trading at $3.84 at the beginning of 2023. Since then, ADCT shares have decreased by 73.2% and is now trading at $1.03. View the best growth stocks for 2023 here .

Are investors shorting ADC Therapeutics?

ADC Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 3,620,000 shares, a decline of 8.8% from the October 31st total of 3,970,000 shares. Based on an average trading volume of 297,800 shares, the short-interest ratio is presently 12.2 days. Approximately 6.8% of the shares of the stock are short sold. View ADC Therapeutics' Short Interest .

When is ADC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our ADCT earnings forecast .

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.03. The business earned $14.49 million during the quarter, compared to the consensus estimate of $14.57 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 1,121.94% and a negative net margin of 145.64%.

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS) , RTX (RTX) , Home Depot (HD) , Procter & Gamble (PG) , Thermo Fisher Scientific (TMO) , Alibaba Group (BABA) , Cisco Systems (CSCO) , Johnson & Johnson (JNJ) and CSX (CSX) .

When did ADC Therapeutics IPO?

(ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO.

Who are ADC Therapeutics' major shareholders?

ADC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (18.46%), Affinity Asset Advisors LLC (1.43%), Acadian Asset Management LLC (0.20%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ADC Therapeutics?

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

ADC Therapeutics Stock Price, News & Analysis (NYSE:ADCT)

$1.03

-0.08 (-7.21%)

(As of 12/5/2023 ET)

Compare

Today's Range: $0.97
▼
$1.09
50-Day Range: $0.47
▼
$1.13
52-Week Range: $0.36
▼
$5.75

Volume: 411,786 shs
Average Volume: 478,315 shs
Market Capitalization: $79.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.75

ADC Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.29 Rating Score
Upside/Downside: 256.0% Upside
$3.67 Price Target
Short Interest: Bearish
6.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.38) to ($1.72) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

514th out of 948 stocks

Pharmaceutical Preparations Industry

224th out of 421 stocks

3.1

Analyst's Opinion

Consensus Rating
ADC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $3.67, ADC Therapeutics has a forecasted upside of 256.0% from its current price of $1.03.
Amount of Analyst Coverage
ADC Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.79% of the float of ADC Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
ADC Therapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
Change versus previous month
Short interest in ADC Therapeutics has recently decreased by 8.82%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ADC Therapeutics does not currently pay a dividend.
Dividend Growth
ADC Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADCT.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for ADC Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 4 people have searched for ADCT on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ADC Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
35.40% of the stock of ADC Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
67.29% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for ADC Therapeutics are expected to grow in the coming year, from ($2.38) to ($1.72) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ADC Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ADC Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ADC Therapeutics has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ADC Therapeutics Stock (NYSE:ADCT)

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBDdimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADCT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ADCT Stock News Headlines

December 1, 2023 | seekingalpha.com

ADC Therapeutics: Navigating A Swirling Drain

November 26, 2023 | benzinga.com

ADC Therapeutics Stock (NYSE:ADCT) Dividends: History, Yield and Dates

December 6, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

November 20, 2023 | markets.businessinsider.com

Analyst Expectations for ADC Therapeutics's Future

November 20, 2023 | finance.yahoo.com

Sobi to present new data at ASH 2023 Annual Meeting

November 15, 2023 | finance.yahoo.com

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

November 10, 2023 | msn.com

TD Cowen Downgrades Adc Therapeutics (ADCT)

November 8, 2023 | finance.yahoo.com

ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call Transcript

December 6, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

November 8, 2023 | finance.yahoo.com

Q3 2023 ADC Therapeutics SA Earnings Call

November 7, 2023 | markets.businessinsider.com

What Wall Street expects from ADC Therapeutics's earnings

November 7, 2023 | finance.yahoo.com

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

November 7, 2023 | finance.yahoo.com

ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards

November 7, 2023 | finance.yahoo.com

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates

November 5, 2023 | morningstar.com

ADC Therapeutics SA ADCT

November 2, 2023 | finance.yahoo.com

Puma Biotech (PBYI) Tops Q3 Earnings Estimates

November 2, 2023 | finance.yahoo.com

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

October 31, 2023 | finance.yahoo.com

ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

October 24, 2023 | finance.yahoo.com

ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023

October 9, 2023 | benzinga.com

Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 – Exclusive Study by The Insight Partners

October 4, 2023 | finance.yahoo.com

Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO

September 5, 2023 | finanznachrichten.de

ADC Therapeutics SA: ADC Therapeutics to Participate in September Investor Conferences

September 5, 2023 | finance.yahoo.com

ADC Therapeutics to Participate in September Investor Conferences

August 30, 2023 | finance.yahoo.com

ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

August 14, 2023 | finance.yahoo.com

Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%

August 11, 2023 | finance.yahoo.com

Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised

August 10, 2023 | msn.com

RBC Capital Maintains Adc Therapeutics (ADCT) Outperform Recommendation

See More Headlines

Receive ADCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:ADCT
CUSIP: N/A
CIK: 1771910
Web: www.adctherapeutics.com
Phone: 41-21-653-0200
Fax: N/A
Employees: 317
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.67
High Stock Price Target: $6.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +458.3%
Consensus Rating: Hold
Rating Score (0-4): 2.29
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-155,800,000.00
Net Margins: -145.64%
Pretax Margin: -148.08%
Return on Equity: -1,121.94%
Return on Assets: -36.23%

Debt

Debt-to-Equity Ratio: 2.57
Current Ratio: 4.80
Quick Ratio: 4.51

Sales & Book Value

Annual Sales: $122.57 million
Price / Sales: 0.65
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.16 per share
Price / Book: 0.89

Miscellaneous

Outstanding Shares: 76,810,000
Free Float: 49,619,000
Market Cap: $79.11 million
Optionable: Not Optionable
Beta: 1.24

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Ameet Mallik M.B.A. (Age 50)
M.S., CEO & Director
Comp: $819.74k
Mr. Jose I. Carmona M.B.A. (Age 51)
Chief Financial Officer
Dr. Patrick van Berkel Ph.D. (Age 55)
Chief Scientific Officer
Dr. Michael Mulkerrin Ph.D. (Age 68)
Chief Technical Operations Officer
Amanda Hamilton
Investor Relations Officer
Ms. Susan Romanus (Age 58)
Chief Compliance & Quality Officer
Mr. Peter J. Graham Esq. (Age 56)
Chief Legal Officer
Ms. Kimberly Pope (Age 56)
Senior VP & Chief People Officer
Ms. Kristen Harrington-Smith (Age 50)
Chief Commercial Officer
Dr. Mohamed Zaki M.D. (Age 58)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ADCT Stock Analysis - Frequently Asked Questions

Should I buy or sell ADC Therapeutics stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADCT, but not buy additional shares or sell existing shares.
View ADCT analyst ratings or view top-rated stocks.
What is ADC Therapeutics' stock price target for 2024?: 6 analysts have issued 12 month price targets for ADC Therapeutics' stock. Their ADCT share price targets range from $2.00 to $6.00. On average, they predict the company's stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 256.0% from the stock's current price.
View analysts price targets for ADCT or view top-rated stocks among Wall Street analysts.
How have ADCT shares performed in 2023?: ADC Therapeutics' stock was trading at $3.84 at the beginning of 2023. Since then, ADCT shares have decreased by 73.2% and is now trading at $1.03.
View the best growth stocks for 2023 here.
Are investors shorting ADC Therapeutics?: ADC Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 3,620,000 shares, a decline of 8.8% from the October 31st total of 3,970,000 shares. Based on an average trading volume of 297,800 shares, the short-interest ratio is presently 12.2 days. Approximately 6.8% of the shares of the stock are short sold.
View ADC Therapeutics' Short Interest.
When is ADC Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ADCT earnings forecast.
How were ADC Therapeutics' earnings last quarter?: ADC Therapeutics SA (NYSE:ADCT) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.03. The business earned $14.49 million during the quarter, compared to the consensus estimate of $14.57 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 1,121.94% and a negative net margin of 145.64%.

What other stocks do shareholders of ADC Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).
When did ADC Therapeutics IPO?: (ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO.
Who are ADC Therapeutics' major shareholders?: ADC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (18.46%), Affinity Asset Advisors LLC (1.43%), Acadian Asset Management LLC (0.20%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of ADC Therapeutics?: Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:ADCT) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ADC Therapeutics Stock Price, News & Analysis (NYSE:ADCT)

ADC Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ADC Therapeutics Stock (NYSE:ADCT)

ADCT Stock Price History

ADCT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ADCT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™